Israeli medical laser manufacturer Lumenis is expecting to raise between $94 million and $107 million when it goes public.
In a regulatory filing Thursday, the company said that it expects to sell 6.3 million shares at a price rangeof $15 to $17. It intends to go public on the Nasdaq under the ticker symbol of LMNS. This medical device IPO would follow the successful IPO of Tandem Diabetes, which makes a touchscreen insulin pump, at the close of 2013 when it raised $125 million.
Lumenis makes lasers for a variety of applications in surgery, urology and for aesthetic procedures. In urology, Lumenis lasers can help in treating enlarged prostates among other things. In gastroenterology, the company makes Holmium lasers are used in tissue ablation, for treating stones and in tissue excision and incision. Lumenis also makes CO2 lasers that can treat certain ear, nose and throat conditions as well as in gynecological use. Other than surgical, the company’s medical lasers are used in ophthalmic and aesthetic procedures.
In 2013, the company garnered $265.4 million in annual revenue, an increase of 6.7% from the year before. Profits skyrocketed 148.6% to $17.4 million in the same period. The company expects that the market opportunity it is targeting is about $3.5 billion.
Here's a video of the company's VersaPulse PowerSuite laser technology.